New Diabetes Pill Mimics Surgery Without the Scalpel—Could It Work?

A new pill designed to mimic the effects of bariatric surgery could offer hope for millions with type 2 diabetes. Glyscend Therapeutics is developing GL200, a treatment that creates a temporary coating in the gut to regulate blood sugar. The approach has already attracted interest from five major drugmakers.

Type 2 diabetes affects over 37 million Americans and remains the seventh leading cause of death in the U.S. While lifestyle changes and medications like insulin help manage the condition, bariatric surgery—particularly gastric bypass—is considered the most effective long-term treatment. However, surgery carries risks, high costs, and is not accessible to all patients.

The duodenum, a section of the small intestine, plays a key role in metabolic regulation. In diabetes patients, this area often functions abnormally. Glyscend's pill, GL200, works by forming a temporary polymer coating along the duodenum. This blocks signals that contribute to high blood sugar, effectively replicating some benefits of bariatric surgery.

GL200 has already completed three human trials, showing promising results in lowering blood sugar levels. But further large-scale studies are needed to confirm its safety and effectiveness. To fund these trials, Glyscend is now seeking partnerships with pharmaceutical giants.

By March 2026, five major companies—Pfizer, Novartis, Roche, AstraZeneca, and Sanofi—had either expressed interest or entered discussions about acquiring or licensing the technology. The pill is designed to pass through the digestive system without entering the bloodstream, reducing potential side effects.

If successful, GL200 could provide a non-invasive, lower-risk alternative to surgery for diabetes patients. The next phase of trials will determine whether the pill can deliver consistent results on a larger scale. Meanwhile, Glyscend continues negotiations with leading drugmakers to advance the project.